170 related articles for article (PubMed ID: 6140171)
1. Neuroleptics have identical potencies in human brain limbic and putamen regions.
Seeman P; Ulpian C
Eur J Pharmacol; 1983 Oct; 94(1-2):145-8. PubMed ID: 6140171
[TBL] [Abstract][Full Text] [Related]
2. Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats.
See RE; Lynch AM; Sorg BA
Neuroscience; 1996 May; 72(1):99-104. PubMed ID: 8730709
[TBL] [Abstract][Full Text] [Related]
3. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain.
Altar CA; Wasley AM; Neale RF; Stone GA
Brain Res Bull; 1986 Apr; 16(4):517-25. PubMed ID: 2872945
[TBL] [Abstract][Full Text] [Related]
4. Regional selectivity of neuroleptic drugs: an argument for site specificity.
Borison RL; Diamond BI
Brain Res Bull; 1983 Aug; 11(2):215-8. PubMed ID: 6138135
[TBL] [Abstract][Full Text] [Related]
5. [The inhibition of dopamine D1 and D2 receptors in human putamen by antipsychotic drugs].
Kobayashi T; Shimizu H; Toru M
Yakubutsu Seishin Kodo; 1990 Jun; 10(2):331-4. PubMed ID: 1979198
[TBL] [Abstract][Full Text] [Related]
6. Differences in the time course of haloperidol-induced up-regulation of rat striatal and mesolimbic dopamine receptors.
Prosser ES; Csernansky JG; Hollister LE
Life Sci; 1988; 43(8):715-20. PubMed ID: 2901023
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonise the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems.
Costall B; Naylor RJ
Eur J Pharmacol; 1976 Nov; 40(1):9-19. PubMed ID: 791660
[TBL] [Abstract][Full Text] [Related]
8. Elevation of brain neuroleptic/dopamine receptors in schizophrenia.
Lee T; Seeman P
Am J Psychiatry; 1980 Feb; 137(2):191-7. PubMed ID: 6101525
[TBL] [Abstract][Full Text] [Related]
9. Abnormal neuroleptic/dopamine receptors in schizophrenia.
Lee T; Seeman P
Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
[TBL] [Abstract][Full Text] [Related]
10. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.
Severson JA; Robinson HE; Simpson GM
Psychopharmacology (Berl); 1984; 84(1):115-9. PubMed ID: 6149590
[TBL] [Abstract][Full Text] [Related]
11. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.
Wilmot CA; Szczepanik AM
Brain Res; 1989 May; 487(2):288-98. PubMed ID: 2525063
[TBL] [Abstract][Full Text] [Related]
12. Thioridazine is not specific for limbic dopamine receptors.
Reynolds GP; Cowey L; Rossor MN; Iversen LL
Lancet; 1982 Aug; 2(8296):499-500. PubMed ID: 6125665
[No Abstract] [Full Text] [Related]
13. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Ogren SO; Hall H; Köhler C; Magnusson O; Lindbom LO; Angeby K; Florvall L
Eur J Pharmacol; 1984 Jul; 102(3-4):459-74. PubMed ID: 6149133
[TBL] [Abstract][Full Text] [Related]
14. The effects of SCH 23390, YM 09151-2, (+)- and (-)-3-PPP and some classical neuroleptics on D-1 and D-2 receptors in rat neostriatum in vitro.
Plantjé JF; Hansen HA; Daus FJ; Stoof JC
Eur J Pharmacol; 1984 Oct; 105(1-2):73-83. PubMed ID: 6208045
[TBL] [Abstract][Full Text] [Related]
15. In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for drug mechanisms of action.
Cohen BM; Lipinski JF
Life Sci; 1986 Dec; 39(26):2571-80. PubMed ID: 2879204
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors.
Tarazi FI; Yeghiayan SK; Baldessarini RJ; Kula NS; Neumeyer JL
Neuropsychopharmacology; 1997 Sep; 17(3):186-96. PubMed ID: 9272485
[TBL] [Abstract][Full Text] [Related]
17. The limbic functional selectivity of amperozide is not mediated by dopamine D2 receptors as assessed by in vitro and in vivo binding.
Svartengren J; Celander M
Eur J Pharmacol; 1994 Mar; 254(1-2):73-81. PubMed ID: 7911431
[TBL] [Abstract][Full Text] [Related]
18. The contrasting effects of neuroleptics on transmitter release from the nucleus accumbens and corpus striatum.
de Belleroche JS; Neal MJ
Neuropharmacology; 1982 Jun; 21(6):529-37. PubMed ID: 6125910
[TBL] [Abstract][Full Text] [Related]
19. Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.
Tam SW; Cook L
Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5618-21. PubMed ID: 6147851
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system.
Bartholini G
J Pharm Pharmacol; 1976 May; 28(5):429-33. PubMed ID: 6752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
